Is Serum YKL-40 Capable of Predicting Intrauterine Growth Restriction (IUGR) and Preeclampsia?
Recruitment status was Active, not recruiting
Objective: To investigate the role of maternal serum YKL-40 and uterine artery doppler, at gestational age 12, 20, 25 and 32 weeks, and the relation to preeclampsia and intrauterine growth restriction. The serum marker YKL-40 is related to conditions involving inflammation, infection, tissue remodeling, fibrosis and cancer. IUGR and preeclampsia are known to be related to inflammation and tissue remodeling.
Methods: women attending screening for downs syndrome is scanned with uterine artery doppler and delivered blood samples at GA 12, 20, 25 and 32 respectively. When pregnancy outcome is registered by medical records blood samples are retrieved and analyzed for serum YKL-40. Serum YKL-40 are correlated to the presence of bilateral notching, preeclampsia and different degrees of intrauterine growth restriction.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||"Kan IUGR og præeclampsi Forudsiges ud Fra YKL-40 målt i Serum?" "Metoder Til at Vurdere om Den Gravide Har Risiko for at Udvikle Svangerskabsforgiftning og/Eller væksthæmning Hos Fosteret".|
Bloodsamples will be collected as well as placenta tissue for histology.
|Study Start Date:||January 2009|
|Estimated Study Completion Date:||September 2012|
|Estimated Primary Completion Date:||November 2011 (Final data collection date for primary outcome measure)|
Pregnant women are included when they attend nuchal transcluency examination and will during their pregnancy be examined 4 times with ultrasound
4 ultrasound examinations during pregnancy and every time a blood sample is colletted. blood sample from the mother and the umbilical cord is collected as well
|Gynækologisk-Obstetrisk Afdeling, Sygehus Nord|
|Roskilde, Region Sjælland, Denmark, 4000|
|Study Director:||Estrid Høgdall, PhD leader||Dept of Pathology Herlev Hospital, Denmark|
|Study Director:||Julia S. Johansen, Dr med prof||Dept. of oncology and medicine, Herlev Hospital, Denmark|